Provided by Tiger Fintech (Singapore) Pte. Ltd.

Zenas BioPharma Inc.

8.25
-0.4800-5.50%
Post-market: 8.250.00000.00%16:23 EDT
Volume:176.22K
Turnover:1.49M
Market Cap:344.84M
PE:-0.69
High:9.08
Open:8.84
Low:8.10
Close:8.73
Loading ...

Is Zenas BioPharma (NASDAQ:ZBIO) In A Good Position To Invest In Growth?

Simply Wall St.
·
13 Mar

Director Makes Bold Move with Major Stock Purchase in Zenas BioPharma!

TIPRANKS
·
12 Feb

BRIEF-Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives

Reuters
·
05 Feb

Zenas Biopharma- Cash Equivalents, Short-Term Investments as of Dec 31 to Fund Operating Expenses & Capex Requirements Into Q4 2026

THOMSON REUTERS
·
05 Feb

Zenas Biopharma :Topline Results From Pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease (Indigo) Expected Year-End 2025

THOMSON REUTERS
·
05 Feb

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

GlobeNewswire
·
05 Feb

Zenas BioPharma Initiated at Outperform by Wolfe Research

Dow Jones
·
04 Feb

Wolfe Research Initiates Coverage on Zenas BioPharma With Outperform Rating, $19 Price Target

MT Newswires Live
·
04 Feb

Zenas BioPharma initiated with an Outperform at Wolfe Research

TIPRANKS
·
04 Feb

Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference

GlobeNewswire
·
28 Jan

Zenas BioPharma initiated with a Buy at H.C. Wainwright

TipRanks
·
17 Dec 2024

HC Wainwright Initiates Zenas BioPharma at Buy With $30 Price Target

MT Newswires Live
·
16 Dec 2024

Zenas BioPharma Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
16 Dec 2024

Zenas Biopharma, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS
·
16 Dec 2024

Zenas BioPharma Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
11 Dec 2024

Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley

TIPRANKS
·
11 Dec 2024